← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
GMS Ventures & Investments
10% Owner | Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001804598
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 2
- Purchases · 24M
- 2
- Average purchase
- $3.8M
- Median purchase
- $3.8M
- Gross purchase value
- $7.5M
Companies: Outlook Therapeutics, Inc.
2 SEC accession(s) · 2 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-08-14 | Outlook Therapeutics, Inc. | OTLK | Director | 10% Owner | $2.5M | Open filing |
| 2026-06-01 | Outlook Therapeutics, Inc. | OTLK | Director | 10% Owner | $5.0M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small Sample | 100.0% (2/2) | 0.0% (0/2) | -12.4% | -12.4% | -13.1% |
| 20D | 2Small Sample | 100.0% (2/2) | 50.0% (1/2) | +38.1% | +38.1% | -13.6% |
| 60D | 1Small Sample | 100.0% (1/1) | 0.0% (0/1) | -27.4% | -27.4% | -27.4% |
| 120D | 0No Data | Awaiting maturity | — | — | — | — |
Research patterns
- First purchase in 12M
- 1/2
- Large purchase ≥ $100k
- 2/2
- Cluster buying · 15D
- 2/2
- Buying the dip
- 2/2
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.